Full history for every metric is available with a Kvantra account
Atreca, Inc. (BCEL)
Key financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 2 | 1 | 2 | 1 | 1 | 1 | 0 |
| Operating profit | $m | -98 | -78 | |||||
| Net profit | $m | -28 | -38 | -67 | -86 | -109 | -97 | -98 |
| EPS reported | $ | -2.35 | -2.43 | |||||
| Operating cashflow per share | $ | -2.09 | -2.09 | |||||
| Capex per share | $ | 0.02 | 0.02 | |||||
| FCF per share | $ | -2.11 | -2.11 | |||||
| Free cash flow | $m | -82 | -65 | |||||
| Net debt | $m | -7 | -21 | |||||
| Book value equity | $m | 78 | - | |||||
| Book value per share | $ | 2.03 | - | |||||
| Number of shares | m | 38.59 | 39.35 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.39 | 0.04 | |||||
| P/S LTM | x | 40.15 | 13.57 | |||||
| P/FCF LTM | x | -0.38 | -0.05 | |||||
| EV/EBITDA LTM | x | -0.71 | 0.25 | |||||
| EV/Sales LTM | x | 83.08 | -67.75 | |||||
| Earnings Yield LTM | % | -314.28% | -2797.1% | |||||
| FCF Yield | % | -263.98% | -1832.1% | |||||
| Quality | ||||||||
| ROE | % | -123.92% | -83.28% | |||||
| ROIC | % | -68.54% | -68.54% | |||||
| Operating margin | % | -12665.6% | -12665.6% | |||||
| Gross margin | % | -819.61% | -819.61% | |||||
| FCF/Sales | % | -10598.2% | -10598.2% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -9.52% | -64.93% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -1.28 | -51.04 | |||||
| Net Debt/EBITDA | x | -0.37 | -0.37 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -21.41% | -599.31% | |||||
| Net debt/Equity | x | -0.08 | - | |||||
| Gross debt/equity | x | 0.81 | - | |||||
Company overview
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Atreca, Inc. (BCEL)
Atreca, Inc. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing antibody-based immunotherapies for various solid tumor indications. Its lead investigational therapeutic, ATRC-101, is a monoclonal antibody distinguished by its novel mechanism of action and a unique target, both identified through the company's proprietary discovery platform. In in vitro studies, ATRC-101 has demonstrated reactivity with a significant proportion of human ovarian, non-small cell lung, colorectal, and breast cancer samples sourced from diverse patient populations. The pipeline also includes APN-122597, a receptor tyrosine kinase engineered to specifically target tumor tissues, and ATRC-501/MAM01, an agent aimed at the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Beyond its internal programs, Atreca maintains strategic alliances, including a collaboration and licensing agreement with Xencor, Inc. for the research, development, and commercialization of innovative CD3 bispecific antibodies in oncology. Additionally, it holds a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the advancement and commercialization of MAM01/ATRC-501, specifically for malaria prevention. Founded in 2010, Atreca, Inc. is headquartered in San Carlos, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free